Kiadis Pharma announces €12 million private placement with a U.S.
healthcare investor
THIS PRESS RELEASE AND THE INFORMATION
CONTAINED HEREIN IS RESTRICTED AND NOT FOR PUBLIC RELEASE,
PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,
NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION
IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS PRESS
RELEASE.
THIS PRESS RELEASE CONTAINS INSIDE
INFORMATION FOR IMMEDIATE RELEASE.
Kiadis Pharma announces €12 million
private placement with a U.S. healthcare investor
Amsterdam, The Netherlands, April 28, 2020 – Kiadis
Pharma N.V. (“Kiadis”, “Kiadis Pharma” or the “Company”) (Euronext
Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, today announces a €12 million private
placement of approximately 7.5 million ordinary shares at a price
of €1.60 per share with a U.S.-based healthcare-focused investment
fund. As part of the transaction, the investor shall receive
approximately 3.75 million warrants with a strike price of €2.22,
which can be exercised over a 5-year period. The Company expects
the transaction to close this week.
Arthur Lahr, CEO of Kiadis commented, “During these volatile
equity capital markets, I am very pleased to announce that we have
successfully completed a private placement to continue to fund the
development of our K-NK-cell therapy programs. We believe that the
outlook for Kiadis over the next several months is promising as we
expect to provide updates at upcoming medical meetings, including
the American Society of Clinical Oncology (ASCO) and the European
Hematology Association (EHA); to initiate our NK REALM study upon
FDA approval of our IND; and to advance our solid tumor program,
while pursuing potential partnerships. We believe that this new
capital will allow us to reach near-term milestones with our K-NK
program that will drive value for all stakeholders.”
The proceeds from this private placement will be used to fund
the development of Kiadis’ K-NK cell therapy programs, including
the clinical development of K-NK002 as an adjunctive therapy for
patients with blood cancer undergoing a hematopoietic stem cell
transplant, the development of K-NK003 for the treatment of acute
myeloid leukemia, and the research and development of the company’s
K-NK platform for solid tumor indications. As of December 31, 2019,
Kiadis had €29.5 million of cash and equivalents on its balance
sheet.
Oppenheimer & Co., Inc. (“Oppenheimer”)
acted as sole placement agent and Bird & Bird acted as legal
advisor to the Company for this transaction. Kiadis’ supervisory
board and management board were advised by Allen & Overy and EY
on the evaluation of various financing alternatives.
About Kiadis Pharma’s K-NK-Cell Therapies
Kiadis Pharma’s K-NK platform is designed to deliver potent NK
cells to help each patient, without the need for genetic
engineering. Kiadis Pharma’s programs consist of off-the-shelf and
haploidentical donor NK-cell therapy products for the treatment of
liquid and solid tumors as adjunctive and stand-alone
therapies.
The Company’s PM21 particle technology enables improved ex vivo
expansion and activation of cytotoxic NK cells supporting multiple
high-dose infusions. Kiadis Pharma’s proprietary off-the-shelf
NK-cell platform is based on NK cells from unique universal donors
and can make NK-cell therapy product rapidly and economically
available for a broad patient population across a potentially wide
range of indications.
Kiadis Pharma is developing K-NK002, which is administered as an
adjunctive immunotherapeutic on top of HSCT, and K-NK003 for the
treatment of relapse/refractory acute myeloid leukemia. In
addition, Kiadis Pharma has pre-clinical programs evaluating
NK-cell therapy for the treatment of solid tumors.
About Kiadis PharmaFounded in 1997, Kiadis
Pharma is building a fully integrated biopharmaceutical company
committed to developing innovative therapies for patients with
life-threatening diseases. With headquarters in Amsterdam, the
Netherlands, and offices and activities across the United States,
Kiadis Pharma is reimagining medicine by leveraging the natural
strengths of humanity and our collective immune system to source
the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext
Amsterdam and Euronext Brussels since July 2, 2015, under the
symbol KDS. Learn more at www.kiadis.com.
Kiadis Pharma Contacts:
Kiadis Pharma:
Maryann Cimino, Sr. Manager, Corporate AffairsTel: +1 (617)
710-7305m.cimino@kiadis.com |
Optimum Strategic
Communications:Mary Clark, Supriya Mathur, Hollie VileTel:
+44 203 950 9144David Brilleslijper (Amsterdam)Tel: +31 610 942
514kiadis@optimumcomms.com |
This press release is released by the Company
and contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 ("MAR"),
encompassing information relating to the private placement, and is
disclosed in accordance with the Company's obligations under
Article 17 of MAR.
For the purposes of MAR and Article 2 of
Commission Implementing Regulation (EU) 2016/1055, this press
release is being made on behalf of the Company by Arthur Lahr,
Chief Executive Officer.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis Pharma’s or, as appropriate,
Kiadis Pharma’s officers’ current expectations and projections
about future events. By their nature, forward-looking statements
involve a number of known and unknown risks, uncertainties and
assumptions that could cause actual results, performance,
achievements or events to differ materially from those expressed,
anticipated or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, regulation, competition and technology, can
cause actual events, performance, achievements or results to differ
significantly from any anticipated or implied development.
Forward-looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the
future. As a result, Kiadis Pharma expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
General
This press release is for information purposes
only and shall not constitute an offer to buy, sell, issue, or
subscribe for, or the solicitation of an offer to buy, sell, issue,
or subscribe for any securities, nor shall there be any offer,
solicitation or sale of securities in any jurisdiction in which
such offer, solicitation or sale would be unauthorised or unlawful
prior to registration or qualification under the securities laws of
any such jurisdiction. Any failure to comply with these
restrictions may constitute a violation of the securities law of
any such jurisdiction.
The new shares and warrants issued, or to be issued, in
connection with the private placement have not been and will not be
registered under the U.S. Securities Act 1933, as amended (the
"U.S. Securities Act") or with any securities
regulatory authority of any state or other jurisdiction of the
United States and may not be offered, sold, delivered or
transferred, directly or indirectly, in or into the United States
except pursuant to an exemption from, or in a transaction not
subject to, the registration requirements of the U.S. Securities
Act and in compliance with any applicable securities laws of any
state or other jurisdiction of the United States. This press
release does not constitute an offer of securities in the United
States, securities may not be offered or sold in the United States
absent registration or an exemption from registration under the
U.S. Securities Act. The Company does not intend to register any
portion of the private placement in the United States or to conduct
a public offering of securities in the United States.
This press release has been issued by and is the
sole responsibility of the Company. No representation or
warranty, express or implied, is or will be made as to, or in
relation to, and no responsibility or liability is or will be
accepted by Oppenheimer (apart from the responsibilities or
liabilities that may be imposed by the regulatory regime
established thereunder) or by any of its affiliates or agents as
to, or in relation to, the accuracy or completeness of this press
release or any other written or oral information made available to
or publicly available to any interested party or its advisers, and
any liability therefor is expressly disclaimed.
Oppenheimer is acting as the sole placement
agent for the Company and for no-one else in connection with the
private placement, and Oppenheimer will not be responsible to
anyone other than the Company for providing the protections
afforded to its customers or for providing advice to any other
person in relation to the Placing or any other matter referred to
herein.
The distribution of this press release and the
offering of the new shares and warrants in certain jurisdictions
may be restricted by law. No action has been taken by the Company,
Oppenheimer or any of their respective directors, officers,
partners, agents, employees, affiliates and advisors that would
permit an offering of such shares or possession or distribution of
this press release or any other offering or publicity material
relating to such shares in any jurisdiction where action for that
purpose is required. Persons into whose possession this press
release comes are required to inform themselves about, and to
observe such restrictions.
The press release does not constitute a
recommendation concerning any investor's options with respect to
the private placement. The new shares and warrants to which this
press release relates may be illiquid and / or subject to
restrictions on their resale. Recipient of this press release
should conduct their own investigation, evaluation and analysis of
the business, data and property described in the press release. The
pricing and value of securities can go down as well as up. Past
performance is not a guide to future performance. The contents of
this press release are not to be construed as financial, legal,
business or tax advice. If you do not understand the contents of
this press release you should consult an authorised financial
adviser, legal adviser, business adviser or tax adviser for
financial, legal, business or tax advice.